Paragon 28 Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Paragon 28 şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.5%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 7GQ şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 7GQ şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Paragon 28 Piyasaya Karşı Temettü Getirisi

7GQ temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (7GQ)	n/a
Pazarın Alt %25'i (DE)	1.8%
Pazarın En İyi %25'i (DE)	4.8%
Sektör Ortalaması (Medical Equipment)	1.9%
Analist tahmini (7GQ) (3 yıla kadar)	0%

Önemli Temettü: 7GQ şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 7GQ şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 7GQ şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 7GQ herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Paragon 28 Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2023)

Paragon 28, Inc. Raises Net Revenue Guidance for 2024

Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Paragon 28, Inc

Johnson Fistel, LLP Announces Class Action Lawsuit Commencement on Behalf of Investors of Paragon 28, Inc

Paragon 28, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Paragon 28, Inc. Launches the Phantom® Fibula Nail System for Less Invasive Fracture Repair

Rosen Law Firm Files Securities Class Action Lawsuit Against Paragon 28, Inc

Paragon 28, Inc. Launches the R3FLEX™? Stabilization System to Anatomically Repair Ankle Syndesmotic In Injury

Paragon 28, Inc. Announces the Launch of SMART28 Case Management Portal

Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2023)

Paragon 28, Inc. Updates Revenue Guidance for the Full Year of 2024

Paragon 28, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2023)

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc. to Report Q1, 2024 Results on May 08, 2024

Paragon 28, Inc. Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler®? R3INFORCE™? Extraosseous Repair System

New major risk - Financial position

Co-Founder recently bought €234k worth of stock

Full year 2023 earnings released: US$0.58 loss per share (vs US$0.88 loss in FY 2022)

Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Paragon 28, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Paragon 28, Inc. Launches Precision®? Mis Bunion System Offering Surgeons A Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

Paragon 28, Inc. Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

New minor risk - Shareholder dilution

Paragon 28, Inc. Launches the Mister Tendon™ Harvester System – the First and Only Minimally Invasive Harvesting System for Fhl and Fdl Tendon Transfer Procedures

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Paragon 28, Inc. Announce the Launch of the Grappler Knotless Anchor System and Bridgeline Tape

Paragon 28, Inc. Launches Beast Cortical Fibers

Third quarter 2023 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2022)

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2023

New minor risk - Share price stability

Paragon 28, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Paragon 28®, Inc. Receives FDA Approval for Ide Feasibility Study of Its Smart Total Talus™ System for Use in Conjunction with the Apex 3D™ Total Ankle Replacement System

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

Paragon 28, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.12 loss in 1Q 2022)

Paragon 28, Inc. Provides Revenue Guidance for the Year 2023

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.26 loss in FY 2021)

Paragon 28, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Paragon 28, Inc. has completed a Follow-on Equity Offering in the amount of $110.5 million.

Paragon 28, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full-Year Ended December 31, 2022

Paragon 28, Inc. Enters Settlement Agreement with Stryker Corp

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 3Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year of 2022

Insider recently sold €1.1m worth of stock

Paragon 28, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Paragon 28, Inc. Announces Board Changes

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.05 loss in 2Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Full Year 2022

Paragon 28, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Paragon 28, Inc.(NYSE:FNA) dropped from Russell 2500 Value Index

Key Executive recently sold €355k worth of stock

Paragon 28, Inc. Launches Monkey Rings™ Circular External Fixation System

Key Executive recently sold €420k worth of stock

Paragon 28, Inc. Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.021 loss in 1Q 2021)

Paragon 28, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new directors

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

Paragon 28, Inc. Launches R3ACT™ Stabilization System for Ankle Injuries

Paragon 28, Inc. to Report Q1, 2022 Results on May 09, 2022

Paragon 28, Inc. Announces Executive Changes

High number of new directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin